Comparison of 2 medium cutoff dialyzers versus on-line hemodiafiltration regarding depurative ability and albumin loss: An uncontrolled clinical research.

Autor: Martínez-Miguel P; Servicio de Nefrología, Hospital Universitario Príncipe de Asturias, Madrid, Spain., Gimena Muñoz R; Servicio de Nefrología, Hospital Universitario Príncipe de Asturias, Madrid, Spain., Barrionuevo González M; Servicio de Bioquímica, Hospital Universitario Príncipe de Asturias, Madrid, Spain., López-Ongil S; Fundación de Investigación Biomédica, Hospital Universitario Príncipe de Asturias, Madrid, Spain., Moro MÁ; Departamento de Farmacología y Toxicología, Facultad de Medicina, Universidad Complutense, Madrid, Spain., Lizasoain I; Departamento de Farmacología y Toxicología, Facultad de Medicina, Universidad Complutense, Madrid, Spain., Rodríguez-Puyol D; Servicio de Nefrología, Hospital Universitario Príncipe de Asturias, Madrid, Spain., García Segura JM; CAI RMN-RSE/BioImaC-ICTS, Facultad de Químicas, Universidad Complutense, Madrid, Spain.
Jazyk: angličtina
Zdroj: Artificial organs [Artif Organs] 2023 Mar; Vol. 47 (3), pp. 589-594. Date of Electronic Publication: 2022 Dec 02.
DOI: 10.1111/aor.14466
Abstrakt: Background: Hemodialysis (HD) techniques that best remove molecules in the middle to high molecular weight range are on-line hemodiafiltration (OL-HDF) and HD with medium cut-off (MCO) membranes. The aim of this study was to compare efficacy and safety of OL-HDF with FxCordiax HDF 800™, with HD with 2 MCO dialyzers: Theranova 500® and the new Elisio 21HX™ dialyzer.
Methods: Fourteen patients following treatment with OL-HDF using FxCordiax HDF 800™ were randomized to receive a consecutive 1-week HD treatment with Theranova 500® and Elisio 21HX™.The reduction rate (RR) of differently sized molecules was compared, as well as the variation rate in molecules smaller than 1000, detected by nuclear magnetic resonance based chemometrics (metabolomics). Albumin loss in dialysate was quantified.
Results: Lower RRs were found for molecules around 20 000 with Elisio 21HX™ compared to OL- HDF (RR prolactin 58.5% versus 66.7%, p = 0.034; RR Kappa light chain 63.1% versus 71.8%, p = 0.010). Albumin loss per session was higher with Theranova 500® than with OL-HDF and with Elisio 21HX™ (2249.9 ± 714.1 mg, 815.2 ± 474.0 mg, 442.9 ± 135.9 mg, p < 0.001, respectively). Metabolomic studies suggested, by semi-quantitative analysis, a greater depurative capacity of OL-HDF, followed by Elisio 21HX™, and then Theranova 500®.
Conclusions: In this study, HD with Theranova 500® has proven to be very similar in efficacy to OL-HDF, although with a significantly higher albumin loss. HD with Elisio 21HX™ resulted in lower removal of molecules around 20 000 compared to OL-HDF, with no significant difference compared to Theranova 500®, and with less albumin loss than Theranova 500®.
(© 2022 International Center for Artificial Organ and Transplantation (ICAOT) and Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje